EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell–Eligible and –Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Gilles Salles, Christopher P Fox, Mehdi Hamadani, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Catherine Thieblemont

Clinical Lymphoma Myeloma and Leukemia · 2025-11 · 25 (11) · e986-e994.e4

DOI: 10.1016/j.clml.2025.07.015 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025-11. Verfasst von Gilles Salles und 10 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: sallesg@mskcc.org. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, AbbVie, NIH NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In the absence of a head-to-head trial of off-the-shelf subcutaneous epcoritamab, a novel CD3xCD20 bispecific antibody, versus chimeric antigen receptor T-cell therapy (CAR T), a matching-adjusted indirect comparison (MAIC) of epcoritamab versus axicabtagene ciloleucel (axi-cel) efficacy was conducted in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with ≥ 2 prior lines of systemic therapy. METHODS: The MAIC used epcoritamab patient-level data from EPCORE NHL-1 (NCT03625037; April 2023 data cutoff) and axi-cel aggregated data from ZUMA-1 (NCT02348216). Patients without prior CAR T were matched to the ZUMA-1 population; weighted regression models were used to estimate absolute differences in overall response rate (ORR) and complete response (CR) rate, and weighted Cox proportional-hazards models were used to estimate hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS). RESULTS: EPCORE NHL-1 included patients without prior CAR T (N = 86, 61.9%) and a CAR T-eligible subset (N = 50, 36.0%) selected via ZUMA-1 inclusion/exclusion criteria. Comparing epcoritamab versus axi-cel, ORR was 73.5% versus 74.3%, respectively (adjusted absolute differences [95% CI]: -0.7% (-18.3, 16.8; P = .933) and CR rate was 48.7% versus 54.5%, respectively (adjusted absolute difference [95% CI] -5.7% [-27.1, 15.7]; P = .599). There was no statistically significant difference in PFS (adjusted HR [95% CI]: 1.009 [0.572-1.778]; P = .975) or OS (adjusted HR [95% CI]: 0.826 [0.444-1.536]; P = .546). Similar results were observed in the CAR T-eligible cohort. CONCLUSION: This MAIC found comparative efficacy between axi-cel and subcutaneous epcoritamab, addressing a critical unmet need for therapeutic alternatives to CAR T for patients with third-line or later relapsed/refractory DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseNeoplasm Recurrence, LocalReceptors, Chimeric AntigenAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMulticenter Studies as TopicClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicBiological Products

Stichwörter der Autor:innen

Bispecific antibodyComparative effectiveness researchDiffuse large B-cell lymphomaHematologic neoplasmsMatching-adjusted indirect comparisonRelapsed or refractory

Substanzen

Antibodies, Bispecificaxicabtagene ciloleucelReceptors, Chimeric AntigenBiological Products

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: sallesg@mskcc.org.
  • School of Medicine, University of Nottingham, Lenton, Nottingham, UK.
  • Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI.
  • AbbVie Inc., North Chicago, IL.
  • Genmab US Inc., Plainsboro, NJ.
  • OPEN Health, Parsippany, NJ.

Förderung

  • NCI NIH HHS
  • AbbVie
  • NIH NCI

Zitieren

APA

Salles, G., Fox, C. P., Hamadani, M., Wang, A., Sail, K., Alshreef, A., Moran, M., Mutebi, A., Blaedel, J., Chirikov, V., & Thieblemont, C. (2025). Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell–Eligible and –Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 25(11), e986-e994.e4. https://doi.org/10.1016/j.clml.2025.07.015

Vancouver

Salles G, Fox CP, Hamadani M, Wang A, Sail K, Alshreef A, et al. Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell–Eligible and –Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2025;25(11):e986-e994.e4. doi:10.1016/j.clml.2025.07.015

BibTeX
@article{Salles2025,
  author = {Salles, Gilles and Fox, Christopher P and Hamadani, Mehdi and Wang, Anthony and Sail, Kavita and Alshreef, Abualbishr and Moran, Michael and Mutebi, Alex and Blaedel, Julie and Chirikov, Viktor and Thieblemont, Catherine},
  title = {Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell–Eligible and –Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  volume = {25},
  number = {11},
  pages = {e986--e994.e4},
  doi = {10.1016/j.clml.2025.07.015}
}
Kostenlos starten →